MedTrace Logo

A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)

NCT02608476 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 732

Last updated 2020-11-20

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

DRUG

CB-03-01 cream, 1%

CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.

DRUG

Vehicle cream

Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.

Sponsors & Collaborators

  • Cassiopea SpA

    lead INDUSTRY

Principal Investigators

  • R&D Cassiopea · Cassiopea S.p.A.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
9 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-16
Primary Completion
2018-02-21
Completion
2018-02-21

Countries

  • United States
  • Bulgaria
  • Georgia
  • Poland
  • Romania
  • Serbia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02608476 on ClinicalTrials.gov